title: Utility of Partial Splenic Embolization for Hypersplenism using Guglielmi Detachable Coils.
abstract: OBJECTIVE
  We examined the utility of partial splenic embolization (PSE) using a Guglielmi Detachable Coil (GDC) comparing its safety and therapeutic efficacy with those of conventional metallic coils (IDC).
  
  
  METHODS
  The GDC group comprised 8 patients who were subjected to embolization using a GDC in combination with an IDC, and the IDC group comprised 13 patients. Treatment factors were evaluated by the total number of coils used. We assessed the mean C-reactive protein (CRP) and the increased rate of platelet counts, 2 weeks after treatment.
  
  
  RESULTS
  The rate of increase in platelet counts at 2 weeks after PSE was 2.47 in the GDC group and 3.18 in the IDC group (p = 0.076). The mean CRP levels were 3.0 in the GDC group and 5.9 in the IDC group (p = 0.14). The mean number of coils were 5.3 in the GDC group and 15.3 in the IDC group and this difference was statistically significant (p = 0.0008).
  
  
  CONCLUSIONS
  A GDC is excellent in terms of stability and allows the operator to conduct embolization of hypersplenism in an accurate and reliable manner. In summary, use of a GDC for hypersplenism reduced the total number of coils required for successful treatment.
authors.forename: Shunichi
authors.initials: S
authors.lastname: Matsuoka
authors.forename: Tomotaka
authors.initials: T
authors.lastname: Ishii
authors.forename: Shoichi
authors.initials: S
authors.lastname: Miyazawa
authors.forename: Taku
authors.initials: T
authors.lastname: Mizutani
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Ito
authors.forename: Shinya
authors.initials: S
authors.lastname: Kamimura
authors.forename: Naoki
authors.initials: N
authors.lastname: Matsumoto
authors.forename: Mitsuhiko
authors.initials: M
authors.lastname: Moriyama
authors.forename: Tadatoshi
authors.initials: T
authors.lastname: Takayama
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000378:metabolism; D004621:Embolization, Therapeutic / Q000009:adverse effects / Q000295:instrumentation*; D004867:Equipment Design; D005260:Female; D006801:Humans; D006971:Hypersplenism / Q000097:blood / Q000175:diagnosis / Q000209:etiology / Q000628:therapy*; D008103:Liver Cirrhosis / Q000150:complications; D008297:Male; D008875:Middle Aged; D010976:Platelet Count; D013157:Splenic Artery; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D002097:C-Reactive Protein